2017 ASCO-SITC Clinical Immuno-Oncology Symposium Dr. Alain Algazi, Associate Clinical Instructor, Department of Medicine (Hematology/Oncology), at the University of California San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center, will present an oral and poster presentation at the ASCO-SITC Clinical Immuno-Oncology Symposium to be held on February 23-24, 2017, in Orlando, FL.
Details of the presentation are as follows:
Abstract Title: Immune monitoring outcomes of patients with stage III/IV melanoma treated with a combination of pembrolizumab and intratumoral plasmid interleukin 12 (pIL-12) (Abstract ID #78) Session Title: Activating the Immune System-New Clinical Approaches Date and Time: February 23, 2017 at 11:30 a.m. – 1:00 p.m. (poster) & 3:30 p.m. – 5:00 p.m. EST (oral) Location: Hyatt Regency Orlando
Further details on this ASCO-SITC oral and poster presentation will be provided in upcoming Company communications. For more information about this symposium, please visit: http://immunosym.org/
The 19th Annual BIO CEO & Investor Conference Mr. Dhillon will present a corporate overview at The 19th Annual BIO CEO & Investor Conference on February 14 at 3:00 p.m. EST at The Waldorf Astoria in New York City.
To view to the live webcast, please access the following link at the time of the presentation: http://www.veracast.com/webcasts/bio/ceoinvestor2017/98226117037.cfm. An archived version of the webcast will be available for 90 days on OncoSec's website: http://www.oncosec.com.
For more information about this conference, please visit: https://www.bio.org/events/bio-ceo-investor-conference
Source Capital Group's 2017 Disruptive Growth & Healthcare Conference Mr. Dhillon will present a corporate overview at Source Capital Group's 2017 Disruptive Growth & Healthcare Conference on February 15 at 3:00 p.m. EST at Convene in New York City.
For more information about this conference, please visit: www.DisruptNYC.com.
About OncoSec Medical Incorporated OncoSec is a biotechnology company developing DNA-based intratumoral immunotherapies with an investigational technology, ImmunoPulse®, for the treatment of cancer. ImmunoPulse® is designed to enhance the local delivery and uptake of DNA-based immune-targeting agents, such as IL-12. In Phase I and II clinical trials, ImmunoPulse® IL-12 has demonstrated a favorable safety profile and evidence of anti-tumor activity in the treatment of various solid tumors as well as a systemic immune response. OncoSec's lead program, ImmunoPulse® IL-12, is currently in clinical development for metastatic melanoma and triple-negative breast cancer. The program's current focus is on the significant unmet medical need in patients with melanoma who are refractory or non-responsive to anti-PD-1/PD-L1 therapies. In addition to ImmunoPulse® IL-12, the Company is also identifying and developing new immune-targeting agents for use with the ImmunoPulse® platform. For more information, please visit www.oncosec.com.
CONTACT: Punit Dhillon President & Chief Executive Officer OncoSec Medical Incorporated 855-662-6732 firstname.lastname@example.org
Media: Laura Radocaj Dian Griesel Int'l. 212-825-3210
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/oncosec-to-present-new-clinical-data-from-phase-2-combination-study-at-asco-sitc-clinical-immuno-oncology-symposium-and-corporate-updates-at-two-investment-conferences-in-february-300403831.html
|SOURCE OncoSec Medical Incorporated|
Copyright©2017 PR Newswire.
All rights reserved
Related biology technology :
1. OncoSec Announces First Quarter Financial Results for Fiscal Year 2017
2. OncoSec Announces Key Corporate Initiatives at Inaugural Investor & Analyst Day on November 17, 2016
3. OncoSec Appoints Sharron Gargosky, PhD, as Head of Clinical Development and Operations
4. OncoSec Opens New Headquarters and Research Facility in San Diego
5. OncoSec Announces First Quarter Results for Fiscal Year End 2016
6. OncoSec to Host First Quarter Financial Results Conference Call on December 8, 2015
7. OncoSec Medical Closes $7.5 Million Registered Direct Offering
8. OncoSec Announces $7.5 Million Registered Direct Offering
9. OncoSec Enrolls First Patient in Biomarker-Focused Pilot Study in Triple Negative Breast Cancer
10. OncoSec Issues Annual Letter To Shareholders
11. OncoSec Announces Fourth Quarter and YTD Results for Fiscal Year End 2015